武汉云克隆科技股份有限公司

细胞程序性死亡蛋白1(PD1)多克隆抗体

Polyclonal Antibody to Programmed Cell Death Protein 1 (PD1)

CD279; PDCD1; SLEB2; HPD1P

  • 细胞程序性死亡蛋白1(PD1)多克隆抗体产品包装(模拟)
  • 细胞程序性死亡蛋白1(PD1)多克隆抗体产品包装(模拟)
  • 细胞程序性死亡蛋白1(PD1)多克隆抗体Used in DAB staining on fromalin fixed paraffin- embedded Kidney tissue
  • PAA751Ra01.jpgWestern Blot; Sample: Lane1: Rat Spleen lysate; Lane2: Mouse Spleen lysate; Lane3: Mouse Thymus lysate Primary Ab: 0.2µg/ml Rabbit Anti-Rat PDCD1 Antibody Second Ab: 0.2µg/mL HRP-Linked Caprine Anti-Rabbit IgG Polyclonal Antibody (Catalog: SAA544Rb19)
  • Certificate通过ISO 9001、ISO 13485质量体系认证

特异性

该抗体是针对PD1的兔多克隆抗体。在免疫组织化学染色和免疫印迹实验中能识别PD1。

用法

Western blotting: 0.2-2µg/mL;
Immunohistochemistry: 5-20µg/mL;
Immunocytochemistry: 5-20µg/mL;
Optimal working dilutions must be determined by end user.

储存

经常使用则4°C保存。-20°C保存不超过两年。避免反复冻融。

稳定性

热稳定性以损失率显示。损失率是由加速降解试验决定，具体方法如下：在37°C孵育48小时，没有显著的降解或者沉淀产生。保质期内，在适当的条件下存储，损失率低于5%。

赠品

相关产品

编号适用物种：Rattus norvegicus (Rat，大鼠)应用(仅供研究使用，不用于临床诊断！)
APA751Ra01细胞程序性死亡蛋白1(PD1)活性蛋白Cell culture; Activity Assays.
RPA751Ra01细胞程序性死亡蛋白1(PD1)重组蛋白Positive Control; Immunogen; SDS-PAGE; WB.
PAA751Ra01细胞程序性死亡蛋白1(PD1)多克隆抗体WB

参考文献

杂志参考文献
OncotargetCirculating soluble programmed death-1 levels may differentiate immune-tolerant phase from other phases and hepatocellular carcinoma from other clinical diseases in chronic hepatitis B virus infection.[pubmed:28545019]
CyberLeninkaПотенциальные биомаркеры эффективности терапии ниволумабом при метастатическом почечно-клеточном раке[:]
АНАЛИЗ РЕЗУЛЬТАТОВ ЛЕЧЕНИЯ БОЛЬНЫХ МЕТАСТАТИЧЕСКИМ РАКОМ ПОЧКИ, ПОЛУЧАВШИХ АНТИ-PD-1‑ТЕРАПИЮ В РАМКАХ ПРОГРАММЫ …[]
International Journal of Molecular SciencesDesign and Synthesis of A PD-1 Binding Peptide and Evaluation of Its Anti-Tumor Activity[Pubmed: 30699956]
PLoS OneClinical significance of soluble programmed cell death-1 and soluble programmed cell death-ligand 1 in patients with locally advanced rectal cancer treated …[Pubmed: 30807610]
CancersPredictive Value of Soluble PD-1, PD-L1, VEGFA, CD40 Ligand and CD44 for Nivolumab Therapy in Advanced Non-Small Cell Lung Cancer: A Case-Control Study[Pubmed: 32085544]